



IN THE U.S. PATENT AND TRADEMARK OFFICE

LARGE ENTITY TRANSMITTAL FORM

April 8, 2004

Sir:

Transmitted herewith is a Supplemental Reply in the above-identified application.

- ☐ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.
- ☐ The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	15	-	37	=	0	\$ 18	\$0.00
INDEPENDENT	3	-	7	=	0	\$ 86	\$0.00
<input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						\$290	\$0.00
						TOTAL	\$0.00

- ☐ Petition for ( ) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). for the extension of time.
- ☒ No fee is required.
- ☐ Check(s) in the amount of is(are) enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Gerald M. Murphy, Jr., #28,977

  
GMM/KLR:gmh  
1422-0386P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment (s)

(Rev. 02/08/2004)



PATENT  
1422-0386P

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANT: Tadamitsu KISHIMOTO et al. CONF.: 3818  
SERIAL NO: 09/367,052 GROUP: 1648  
FILED: August 6, 1999 EXAMINER: Z. LUCAS  
FOR: NOVEL MOUSE CXC CHEMOKINE RECEPTOR

**SUPPLEMENTAL REPLY UNDER 37 C.F.R. § 1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

April 8, 2004

Sir:

Further to Applicants Reply under 37 C.F.R. § 1.111 filed on March 24, 2004, the following supplemental remarks are respectfully submitted in connection with the above-identified application.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks** begin on page 10 of this paper.